Valbiotis is a commercially oriented Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach by developing a new class of health nutrition products designed to reduce the risk of major metabolic and cardiovascular diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.
Created at the beginning of 2014 in La Rochelle, the Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Company Details
- Employees
- 59
- Founded
- -
- Address
- 12f Rue Paul Vatine, Périgny,nouvelle-Aquitaine 17180,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- valbiotis.com
- Keywords
- Metabolic diseases, Diabetes, prediabetes, health, prevention, NASH, microbiota, microbiome, innovation, NAFLD, Blood pressure, cholesterol, cardiovascular diseases, sante.
- HQ
- Périgny, Nouvelle-Aquitaine
Valbiotis Questions
Valbiotis's website is valbiotis.com
Valbiotis's LinkedIn profile is https://fr.linkedin.com/company/valbiotis
Valbiotis has
59 employees.
View email and phone details for 59
employees at Valbiotis.
Valbiotis's industry is
Biotechnology Research
Valbiotis's top competitors are
Nexbiome Therapeutics,
Apha Biomat,
Biopole Clermont-Limagne,
Meccellis Biotech,
Cryoport Systems (Formerly Cell&co),
Ans Biotech,
Pileje,
Biose Industrie,
Dômes Pharma,
Carbogen Amcis.
Valbiotis's categories are Biotechnology Research
Valbiotis's founding year is 2014
